10.25384/SAGE.12311066.v1
Helmut Butzkueven
Helmut
Butzkueven
Maria Trojano
Maria
Trojano
Ludwig Kappos
Ludwig
Kappos
Tim Spelman
Tim
Spelman
Heinz Wiendl
Heinz
Wiendl
Karen Rosales
Karen
Rosales
Ray Su
Ray
Su
Stephanie Licata
Stephanie
Licata
Pei-Ran Ho
Pei-Ran
Ho
Nolan Campbell
Nolan
Campbell
MSJ917925_supplemental_table_1 – Supplemental material for Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri<sup>®</sup> Observational Program (TOP)
SAGE Journals
2020
Discontinuation
disease-modifying therapy
multiple sclerosis
natalizumab
observational study
relapse
2020-05-15 12:10:40
Journal contribution
https://sage.figshare.com/articles/journal_contribution/MSJ917925_supplemental_table_1_Supplemental_material_for_Clinical_outcomes_in_patients_who_discontinue_natalizumab_therapy_after_2_years_in_the_Tysabri_sup_sup_Observational_Program_TOP_/12311066
<p>Supplemental material, MSJ917925_supplemental_table_1 for Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri<sup>®</sup> Observational Program (TOP) by Helmut Butzkueven, Maria Trojano, Ludwig Kappos, Tim Spelman, Heinz Wiendl, Karen Rosales, Ray Su, Stephanie Licata, Pei-Ran Ho and Nolan Campbell in Multiple Sclerosis Journal</p>